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The diagnostic and prognostic usefulness of copeptin were evaluated in septic patients, as compared to procalcitonin assessment. In
this single centre and observational study 105 patients were enrolled: 24 with sepsis, 25 with severe sepsis, 15 with septic shock, and
41 controls, divided in two subgroups (15 patients with gastrointestinal bleeding and 26 with suspected SIRS secondary to trauma,
acute coronary syndrome, and pulmonary embolism). Biomarkers were determined at the first medical evaluation and thereafter
24, 48, and 72 hours after admission. Definitive diagnosis and in-hospital survival rates at 30 days were obtained through analysis
of medical records. At entry, copeptin proved to be able to distinguish cases from controls and also sepsis group from septic shock
group, while procalcitonin could distinguish also severe sepsis from septic shock group. Areas under the ROC curve for copeptin
and procalcitonin were 0.845 and 0.861, respectively. Noteworthy, patients with copeptin concentrations higher than the threshold
value (23.2 pmol/L), calculated from the ROC curve, at admission presented higher 30-day mortality. No significant differences
were found in copeptin temporal profile among different subgroups. Copeptin showed promising diagnostic and prognostic role
in the management of sepsis, together with its possible role in monitoring the response to treatment.
1. Introduction
Sepsis, severe sepsis, and septic shock are among the leading
causes of death in the Emergency Departments and Intensive
Care Units [1]. It is estimated that there are more than
1.000.000 cases of sepsis among hospitalized patients each
year in USA [2]. Prompt diagnosis and therapy administra-
tion are considered key features to improve septic patient
outcomes as indicated in the most recent sepsis guidelines
published in 2013 by Surviving Sepsis Campaign [3], even if
the EGDT (Early Goal-Directed Therapy) protocol efficacy
has been questioned by several studies [4, 5]. The use of
biomarkers may be useful in the detection of infection and
in the management of the septic patient; despite the fact that
more than 100molecules have been evaluated in sepsis [6], an
ideal biomarker, that is to say a molecule which, at the same
time, allows early diagnosis, risk stratification, monitoring
of clinical response to therapy, and prediction of outcome
[7], is still missing. Procalcitonin (PCT) is the reference
biomarker in the diagnosis of sepsis: plasma levels more than
two standard deviations above the normal value are part
of the sepsis definition [3]. Moreover, PCT may be useful
in helping the physician in the decision of discontinuing
the antibiotic therapy therefore limiting antibiotic overuse
[8]. Copeptin is a 39-amino acid glycopeptide derived from
preprovasopressin and it is cosecreted in the bloodstream
with vasopressin in an equimolar ratio in response to osmotic
and hemodynamic changes. It is slowly degraded and in
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Table 1: Demographic and clinical characteristics of the study population.
Controls (𝑁 = 41)
Sepsis (𝑁 = 24) Severe sepsis (𝑁 = 25) Septic shock (𝑁 = 15)SIRS (𝑁 = 26)
GI bleeding (𝑁 = 15)
Females (𝑁) 28 11 16 11
Males (𝑁) 13 13 9 4
Age (years) 53.4 (18–92) 67.1 (20–85) 68.8 (50–83) 77.5 (66–93)
SAPSS II 31 (15–54) 28 (13–52) 35 (20–50) 46 (35–60)
SOFA 3 (0–6) 2 (0–7) 3 (0–7) 9 (5–12)
Blatchford 13 (9–18)
Values are expressed as mean and range. SIRS: systemic inflammatory response syndrome; GI bleeding: gastrointestinal bleeding; SAPS II: Simplified Acute
Physiology Score; SOFA score: Sequential Organ Failure Assessment score.
healthy individuals normal values of copeptin range between
1.70 and 11.25 pmol/L [9]. Copeptin physiological role(s) in
the circulation is not yet known; nevertheless it is used
in routine assessment instead of vasopressin, because of its
easier measurability. As a matter of fact copeptin has been
used to evaluate the role of vasopressin in pathophysiology
[10]; its measurement proved to be useful as a novel approach
for diabetes insipidus (DI) diagnosis, allowing the distinction
between central complete and nephrogenic DI. Moreover,
increased level of copeptin is related to higher mortality in
patients with chronic and acute heart failure. In the study
by Voors et al. [11] copeptin is shown to be a stronger
biomarker in prediction of death and cardiovascular events
than both BNP (brain natriuretic peptide) and NT-pro-
BNP (N-terminal pro-BNP) in a population of patients
with heart failure after acute myocardial infarction. Clinical
conditions like severe sepsis and septic shock are responsible
for a relevant secretion of copeptin and vasopressin, causing
a function impairment of the latter. This impairment is
thought to be partially responsible of human body’s inability
to reestablish a correct vascular tone in the patient suf-
fering from septic shock [12]. Based on these premises,
we compared copeptin with PCT in terms of diagnostic
and prognostic efficacy in an adult population admitted
to the Emergency Department (ED) with SIRS (systemic
inflammatory response syndrome) or active gastrointestinal
bleeding (control group) and suspected sepsis, severe sepsis,
and septic shock (study group).
2. Materials and Methods
2.1. Study Design and Patients. We conducted a single cen-
tre and observational study on patients presenting to ED
with diagnosis of gastrointestinal bleeding, SIRS and either
confirmed or suspected sepsis, severe sepsis, and septic
shock at the first medical evaluation. Patient enrollment was
conducted in an eight-month period. An informed consent
to participate in the study, in accordance with the principles
of Ethics Committee of Turin University Hospital based
on the Declaration of Helsinki (1964), was obtained from
each patient. Sixty-four patients (26 females and 38 males)
were referred to the ED of Citta` della Salute e della Scienza
University Hospital of Turin with the suspicion of sepsis,
severe sepsis, or septic shock and forty-one subjects (13
females and 28 males) affected by SIRS or gastrointestinal
bleedingwere enrolled as cases and controls, respectively.The
inclusion criteria were patients who could undergo a blood
test at the admission (T0) and thereafter at 24 (T1), 48 (T2),
and 72 (T3) hours after enrollment, presence of at least two
clinical criteria for SIRS, suspected diagnosis of sepsis, severe
sepsis, and septic shock (according to the American College
of Chest Physicians/Society of Critical CareMedicine and the
International Surviving Sepsis Campaign Guidelines Com-
mittee) [3], and patients with diagnosis of gastrointestinal
(GI) bleeding at first medical evaluation. Exclusion criteria
were patients unable to provide informed legal consent,
age less than 18 years, patients with previous diagnosis
of endocrine disease involving the hypothalamic-pituitary
gland axis, and patients dismissed or deceased with new
diagnosis of endocrine disease involving the hypothalamic-
pituitary gland axis. On admission to the ED, clinical and bio-
chemical data were collected before any medical treatment;
using clinical parameters and blood test results, Simplified
Acute Physiology Score (SAPS II) [13] and Sequential Organ
FailureAssessment (SOFA) score [14] were calculated. For the
gastrointestinal bleeding control group also the Blatchford
score has been calculated [15]. In Table 1 demographic and
clinical characteristics of the recruited patients are shown.
The analysis of digital medical records and the criteria of the
International Guidelines for Management of Severe Sepsis
and Septic Shock [3] were used to obtain definitive diagnosis
(SIRS, sepsis, severe sepsis, septic shock, and GI bleeding);
the prognostic role of copeptin was assessed by correlating its
values to the in-hospital mortality at 30 days.
2.2. BiomarkerMeasurements. Collected samples were stored
at −70∘C and were subsequently analyzed for procalci-
tonin and copeptin in the Clinical Biochemistry Laboratory.
Copeptin concentrations were determined using the BRA-
HAMS KRYPTOR compact PLUS automated method, which
requires 20 minutes to be completed. It is a quantitative test
that allows the assessment of CT-pro-AVP (C-terminal por-
tion of proarginine-vasopressin or copeptin) concentrations
in human serumor plasma (EDTA, heparin) by time-resolved
amplified cryptate emission (TRACE) technique which mea-
sures the signal that is emitted from an immunocomplex
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with time delay. The assay has a functional sensitivity of
0.9 pmol/L; imprecision evaluation tests yielded a within-run
variation of less than 7% and a between-run variation of less
than 12% on a wide range of values. Procalcitonin concen-
trations were measured by the method Elecsys BRAHMS
PCT (Roche Diagnostics). It is an electrochemiluminescence
immunoassay (ECLIA) for the in vitro quantitative determi-
nation of the concentration of procalcitonin (PCT) in serum
or plasma. The test took about 18 minutes and the assays
were performed automatically on the analyzer e601 Cobas
(Roche Diagnostics, Mannheim, Germany). Within-series
and between-series coefficient of variations were <6% and
<13% on different sample concentrations, and the functional
sensitivity has been calculated <0.02 ng/mL.
2.3. Statistical Analysis. The One-Way Analysis of Variance
(ANOVA) followed by Student-Newman-Keuls 𝑡-test was
used to evaluate differences among the five patient popu-
lations and to compare the diagnostic efficacy of biomark-
ers in the study. The diagnostic accuracy at admission of
study biomarkers was evaluated through the analysis of
the ROC (Receiving Operator Characteristic) curves. The
prognostic role of copeptin values at entry was estimated
through Kaplan-Meier curve. Serial measurement analysis
was applied to assess differences in the areas under the curve
of biomarker temporal profiles over a 72-hour interval. Both
within- and between-group differences among biomarker
concentrations detected at admission and thereafter at 24, 48,
and 72 hours were tested by ANOVA for repeated measures.
Statistical analysis and graphing were performed using the
software MedCalc (MedCalc Software, Belgium). A 𝑝 value
< 0.05 was considered to be significant.
3. Results
The study was carried out on a total of 105 patients: 15 were
diagnosed with gastrointestinal bleeding, 26 were suffering
from a condition of SIRS without evidence of infectious out-
break, 24 were diagnosed with sepsis, 25 were diagnosed with
severe sepsis, and 15 were diagnosed with septic shock. The
ANOVA test proved to be significant for both copeptin and
PCT. The median copeptin concentrations were 70.1 pmol/L
(range 2.95–500.1) in the gastrointestinal bleeding group,
5.2 pmol/L (1.25–117.8) in the SIRS group, 34.2 pmol/L (7.9–
220.1) in the sepsis group, 61.8 pmol/L (2.5–527.7) in the
severe sepsis group, and 128.7 pmol/L (12.0–425.0) in the
septic shock group (Figure 1).
Upon arrival to the Emergency Department, copeptin
concentrations were significantly higher in patients with
septic shock than in those with sepsis (𝑝 = 0.02); moreover
copeptin concentrations were significantly different between
SIRS group and septic population (𝑝 < 0.05). The gastroin-
testinal bleeding controls showed very high concentrations of
copeptin but no statistically significant difference has been
observed between this group and septic population (𝑝 >
0.05). Interestingly, C-reactive protein (CRP) concentrations
were very similar in the three populations of septic patients,
and no statistically significant differences were found among
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Figure 1: Distribution of copeptin concentrations obtained at
admission (T0) in the studied groups. Box-and-whisker plot rep-
resents median, first, and third quartile, as well as minimum and
maximum values.
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Figure 2: Distribution of procalcitonin (PCT) concentrations mea-
sured at entry (T0) in the studied groups. Box-and-whisker plot
represents median, first, and third quartile, as well as minimum and
maximum values.
studied groups except for the gastrointestinal bleeding con-
trols, presenting with lower values. Accordingly, no corre-
lations were observed between copeptin and PCR levels in
our study. PCT concentrations in gastrointestinal bleeding,
SIRS, sepsis, severe sepsis, and septic shock groups were
0.15 ng/mL (0.02–1.03), 0.03 ng/mL (0.02–12.3), 0.39 ng/mL
(0.04–3.21), 0.74 ng/mL (0.08–49.11), and 10.10 ng/mL (0.34–
100.00), respectively (Figure 2).
PCT concentrations were similar in SIRS and gastroin-
testinal bleeding groups (𝑝 = 0.2772). The biomarker
distinguished the septic population from controls (𝑝 < 0.05),
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Figure 3: Comparison between ROC curves obtained for copeptin
and procalcitonin (PCT) on samples collected at the admission to
the Emergency Department.
and its concentrations were significantly different among
sepsis, severe sepsis, and septic shock groups.
The analysis of the diagnostic role of the two biomarkers
was focused only on the four groups of patients with sus-
pected sepsis or septic shock. The ROC curve of copeptin
shows an AUC of 0.845. The best cut-off in terms of diag-
nostic accuracy was found at a copeptin concentration of
23.2 pmol/L, with 74% sensitivity and 87% specificity. The
AUC for PCT ROC curve was 0.861 and the best cut-off
in terms of diagnostic accuracy was found at PCT levels
of 0.090 ng/mL, with 96% sensitivity and 73% specificity. A
statistically significant difference between the ROC curves of
copeptin and PCT was not observed (𝑝 = 0.85) (Figure 3).
Regarding the prognostic effectiveness of copeptin, plac-
ing as limit the value of 23.2 pmol/L, obtained from the anal-
ysis of the ROC curve, and considering the deaths up to 30
days, it can be deduced that individuals with concentrations
of copeptin on admission higher than the threshold value
were burdened by a higher mortality (𝑝 = 0.047) (Figure 4).
By comparing the area under the curve of temporal
profiles of the two biomarkers, until 72 hours after enroll-
ment, serial measurement analysis showed some differences
among the populations with sepsis, severe sepsis, and septic
shock. As regards copeptin, this difference did not reach
statistical significance; however, it was possible to observe a
different trend among the patients’ populations, particularly
among patients diagnosed with sepsis and those diagnosed
with severe sepsis or septic shock. The temporal profile of
PCT concentrations, on the other hand, showed a signifi-
cant difference between the three populations, in particular
between sepsis and septic shock, demonstrating the utility
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Figure 4: Kaplan-Meier survival curves related to copeptin con-
centrations at admission to the Emergency Department. A: patients
with initial copeptin concentrations higher than 23.2 pmol/L;
B: patients with copeptin concentrations at entry lower than
23.2 pmol/L.
of PCT in monitoring the evolution of the clinical response
to treatment. These observations were confirmed by the
ANOVA for repeated measures, demonstrating a statistically
significant reduction in PCT concentrations from T0 to T72
(𝑝 < 0.0001), with significant differences both within- and
between-groups.The same analysis performed with copeptin
results revealed only small between-group differences in
biomarker fluctuations over time, even if more pronounced
and near the statistical significance for the high risk group of
septic shock patients.
4. Discussion
Sepsis, which is a systemic inflammatory response secondary
to infection, is responsible for an endocrine dysfunction char-
acterized by inappropriately low levels of vasopressin, sick
euthyroid syndrome, reduced adrenal response to ACTH,
insulin resistance, and hyperglycemia [16]. In the early stages
of septic shock, sepsis-induced hypotension is one of the
main stimuli of vasopressin secretion, causing an increase in
the hormone serum levels which contributes to the mainte-
nance of arterial pressure [17]; subsequently a rapid decline
is observed, due to vasopressin stores depletion. Vasopressin
function impairment is one of the many factors leading to
development of the decrease of arterial pressure [12] and
prolonged hypotension and the resulting hypoperfusion leads
to organ failure; maintenance of and adequate level of mean
arterial pressure (MAP) is a main goal in the management
of septic shock [18]. Unfortunately, reliable measurement
of plasma vasopressin concentrations is difficult due to its
short half-life (24 minutes), its small size, and the complex
preanalytical steps required [9]. Copeptin, which is the C-
terminal fragment of provasopressin peptide (CT-proAVP)
and is coreleased in an equimolar ratio with vasopressin,
instead, is a stable peptide in EDTAplasma and can be used as
a surrogate biomarker of arginine vasopressin [10]. Copeptin
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has been evaluated as biomarker for several illnesses such as
stroke [19] or heart failure [20], showing a promising role
mainly as a prognostic biomarker. In a recent study copeptin
levels seem to be strongly related to short-, mid-, and long-
term mortality in unselected patients admitted to hospital
showing that copeptin could be a valuable prognostic tool
in the most frequent disease entities [21]; moreover, together
with other stressmarkers, it could be used in risk stratification
of patients presenting to the ED with nonspecific complaints
[22].
Several studies that highlight the role of copeptin as
prognostic factor of increased risk in sepsis and septic shock
have also been published. Copeptin levels increase progres-
sively with the severity of sepsis in ventilator associated
pneumonia (VAP) [23], copeptin plasma concentrations in
patients with sepsis are positively related to APACHE II score
and reflect disease severity [24], and elevated copeptin levels
in patients with septic or haemorrhagic shock [25] predict
poor outcomes.
With the aim to verify whether copeptin could be useful
as a biomarker of sepsis we designed a single centre study in
which we evaluated the role of copeptin compared to PCT in
the management of patients referred to the ED of a tertiary
care referral teaching hospital with suspected sepsis, severe
sepsis, and septic shock. Overall, we evaluated 105 patients
divided in four groups according to the definition criteria
of SIRS, sepsis, severe sepsis, and septic shock validated by
the most recent International Guidelines. The control group
population included subjects with SIRS and also subjects with
active gastrointestinal (GI) bleeding. The choice of including
patients with GI bleeding in the control group was made
in order to evaluate copeptin trend in those patients with
an hemodynamic alteration due to an hypovolemic and not
distributive stress. For both biomarkers we determined diag-
nostic accuracy on admission, as well as temporal profile in
blood concentrations at 24, 48, and 72 hours after admission.
Prognostic effectiveness of copeptin concentrations related to
mortality at 30 days after enrollment was also evaluated.
Our data suggest a potential use of copeptin as diagnostic
tool in a population of patients referred to the ED with sus-
pected sepsis. In this study copeptin is shown to be superior
toCRP in distinguishing the population of patients diagnosed
with septic shock from those diagnosedwith sepsis. Copeptin
secretion is associated with a reactive response to important
changes in blood volume, as seen in septic and haemorrhagic
shock [25]; in the present study the septic shock group and the
control group of patients with GI bleeding have high levels
of copeptin plasma concentrations. It cannot be excluded,
however, that proinflammatory stimuli and activation of
the immune system can induce the increase of copeptin
concentrations in septic shock, as in the case of procalcitonin,
since it has been shown that inflammatory mediators such as
interleukin-1𝛽 (IL-1𝛽) and Tumor Necrosis Factor-𝛼 (TNF𝛼)
stimulate the secretion of AVP and copeptin [26].
The threshold limit value calculated in our study
(23.2 pmol/L) differs from the one proposed byMorgenthaler
et al. (96 pmol/L) [25]. This difference could be due to
different criteria used in patient enrollment and to sample
size.
In the analysis of the potential benefits deriving from the
use of copeptin in predicting the outcomes of a population of
critically ill patients, the role of this biomarker as prognostic
index on survival cannot be overlooked, already documented,
and confirmed also in this study. In fact, our observations
prove that patients with lower concentrations of copeptin
on admission have a lower probability of dying. It could be
useful to evaluate copeptin as a prognostic factor for other
endpoints different frommortality (length of hospitalization,
length of treatment with elevated costs, and long-term sepsis-
induced organ damage) and as an independent prognostic
index when compared with other variables related to risk
(clinical scores, biohumoral values like lactate levels, and
hemodynamic parameters).
In this regard, the assessment of the temporal profile
of the two biomarkers concentrations in the first 72 hours
after admission has been performed. This analysis showed,
in agreement with data reported in the literature [27, 28],
the utility of PCT in monitoring the evolution of the clinical
response to treatment, particularly for the population of
patients diagnosed with severe sepsis or septic shock, which
present a significantly different trend of serial concentrations
when compared to the population of subjects with a diagnosis
of sepsis. Copeptin showed a similar behaviour, although not
reaching statistical significance a different trend is observed
in the group of patients diagnosed with sepsis, suggesting
a possible application of copeptin also in monitoring the
clinical response to treatment in these populations.
To the best of our knowledge, a multibiomarker approach
that involves both PCT and copeptin needs to be evaluated
yet. When compared to classical inflammation biomarkers
[29], like PCT, copeptin seems to have a lower diagnostic
capacity. Nevertheless, considering the differences in the
induction of both biomarkers in a complex pathophysiolog-
ical contest such as that represented by the continuum of
sepsis, an approach based on a combined use of the two
biomarkers should be evaluated on a larger sample size in
order to assess the degree of additional information and the
impact on clinical decision-making that this approach could
offer. In such assessment a careful examination of the cost
benefit ratio must be inevitably included.
5. Conclusions
With this study we demonstrate the potential role of copeptin
in the management of patients referring to the Emergency
Department with suspected sepsis in three different areas
of application: diagnosis, prognosis, and monitoring. Results
related to diagnostic potential of copeptin show that this
biomarker is able to differentiate between the populations and
stratify the disease severity, in particular patients diagnosed
with sepsis from patients diagnosed with septic shock. As
prognostic index, lower concentrations of copeptin on admis-
sion are related to lower mortality. Unlike PCT, copeptin
levels monitoring is not statistically significant, although a
different trend is observable between the sepsis group and
the severe sepsis and septic shock groups. Presented data
highlight the need to investigate and confirm the diagnostic
6 BioMed Research International
and prognostic role of copeptin, as well as its possible use
in the monitoring of the disease evolution of patients with
suspected sepsis, with further studies based on larger sample
size.
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